Activity Evaluation and Mode of Action of ICA Against Toxoplasma gondii In Vitro
Biomolecules · 2025
DOI: 10.3390/biom15020202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Yanhua Qiu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou 730050, China. Hauptthemen laut MEDLINE: Toxoplasma, Antiprotozoal Agents, Pyridines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Innovation Project of Chinese Academy of Agricultural Sciences, the Earmarked Fund for China Agriculture Research System.
Abstract (Originalsprache)
Toxoplasmosis is a significant zoonotic parasitic disease. Currently, there is no effective vaccine available to prevent human infection, and treatment primarily relies on chemotherapy. However, the lack of specific therapeutic agents and the limitations of existing drugs highlight the urgent need for novel, safe, and effective anti-Toxoplasma gondii (T. gondii) medications. In this study, we evaluated the toxicity of ICA (N-(pyridin-2-yl)-4-(pyridine-2-yl)thiazol-2-amine) to host cells and assessed its inhibitory and anti-proliferative effects on T. gondii tachyzoites. We further investigated the impact of ICA on the ultrastructure of T. gondii using transmission electron microscopy (TEM). Additionally, we measured alterations in mitochondrial membrane potential, superoxide levels, and ATP levels in T. gondii to assess the effect of ICA on mitochondrial function. Our findings demonstrated that ICA exhibits a safe and effective inhibitory effect on T. gondii, with a selectivity index (SI) of 258.25. Notably, ICA demonstrated a more potent anti-proliferative effect than pyrimethamine (PYR). Ultrastructural observations revealed that ICA induces mitochondrial swelling and membrane rupture in T. gondii. Further investigations confirmed that ICA leads to mitochondrial dysfunction in T. gondii. In conclusion, our results suggest that ICA possesses the potential to serve as a lead compound for the development of novel anti-T. gondii therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of New Animal Drug Project of Gansu Province, Lanzhou 730050, China.
- Key Laboratory of Veterinary Pharmaceutical Development, Ministry of Agriculture and Rural Affairs, Lanzhou 730050, China.
- Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou 730050, China.
ORCID-Profile: Yanhua Qiu
Förderung
- the Innovation Project of Chinese Academy of Agricultural Sciences
- the Earmarked Fund for China Agriculture Research System
Zitieren
APA
Qiu, Y., Wang, W., Wang, Q., Xu, J., Dai, G., Bai, Y., & Zhang, J. (2025). Activity Evaluation and Mode of Action of ICA Against Toxoplasma gondii In Vitro. Biomolecules. https://doi.org/10.3390/biom15020202
Vancouver
Qiu Y, Wang W, Wang Q, Xu J, Dai G, Bai Y, et al. Activity Evaluation and Mode of Action of ICA Against Toxoplasma gondii In Vitro. Biomolecules. 2025. doi:10.3390/biom15020202
BibTeX
@article{Qiu2025,
author = {Qiu, Yanhua and Wang, Weiwei and Wang, Qing and Xu, Jing and Dai, Guonian and Bai, Yubin and Zhang, Jiyu},
title = {Activity Evaluation and Mode of Action of ICA Against Toxoplasma gondii In Vitro},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15020202}
}
EUVIMED